Dasatinib or higher-dose imatinib for chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two different medicines for people with chronic myeloid leukemia (CML) whose current treatment with imatinib (Gleevec) has not worked well enough. It tests whether switching to dasatinib (Sprycel) or increasing the dose of imatinib to 600 mg helps get the disease under better control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic myeloid leukemia (CML) with the Philadelphia chromosome or BCR-ABL gene.
- You are currently taking imatinib (Gleevec) at the standard dose (400 mg daily) but it is not working well enough – your blood counts or genetic test results are not meeting the expected milestones.
- You have not taken dasatinib (Sprycel) before.
- You are not pregnant or breastfeeding, and you are not planning to conceive during the study.
- You have not had a bone marrow transplant (stem cell transplant) previously.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, dasatinib and ropeginterferon, for people newly diagnosed with chronic myeloid leukemia (CML) in its early chronic phase. The goal is to see if the combination works safely and helps control the disease.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial studies whether a generic version of imatinib (Carcemia®) works as well and is as safe as Glivec® in real-life care for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). It may help confirm that the generic option is effective for controlling the disease.
This trial tests a new drug combination for people with chronic myeloid leukemia (CML) that has not responded well enough to their first treatment. The goal is to see if adding or combining these drugs can better control the leukemia.
This trial tests a new pill, asciminib, as the first treatment for people newly diagnosed with chronic myeloid leukemia (CML) in its early phase. The goal is to see if it can control the disease with fewer side effects than standard treatments.
This study compares two oral medications, flumatinib and imatinib, to see which is more effective and safer for people newly diagnosed with chronic myeloid leukemia in its early phase. It aims to help doctors choose the best initial treatment.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.